NL-OMON44299
Completed
Not Applicable
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma - PSMA-PET imaging for advanced ACC/SDC
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Radboud Universitair Medisch Centrum
- Enrollment
- 25
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- locally advanced, recurrent or metastatic ACC or SDC
- •\- Age \* 18 years old
- •\- Ability to provide written informed consent
Exclusion Criteria
- •\- Contra\-indication for PET imaging: pregnancy, breast feeding, severe claustrophobia
- •\- Impaired renal function: MDRD \<30 ml/min/1,73 m2
- •\- Impaired liver function: AST and ALT \* 2\.5 x ULN (\*5 x ULN for patients with liver metastases)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
PSMA-PET scan for incurable or metastatic salivary gland cancerEUCTR2017-002093-40-NLRadboudumc25
Active, not recruiting
Phase 1
Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumorsadvanced/metastatic solid tumorsMedDRA version: 20.0Level: LLTClassification code 10027477Term: Metastatic carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-004376-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS400
Recruiting
Phase 2
PETCT and MRI guided boost for prostate cancer radiotherapyHealth Condition 1: C61- Malignant neoplasm of prostateCTRI/2022/09/045258Varian Medical System
Active, not recruiting
Phase 1
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2016-000842-79-BEInstitut Jules Bordet75
Active, not recruiting
Phase 1
Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis.Sarcoidosis.Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2016-002160-14-NLSt. Antonius Hospital